Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study 

T. Else reports support from MSD during the conduct of the study, as well as personal fees from MSD, Lantheus, and HRA Pharma outside the submitted work. E. Jonasch reports grants from MSD during the conduct of the study. E. Jonasch also reports grants from Aveo, Arrowhead, Corvus, MSD, NiKang, and Telix, as well as honoraria from Aveo, DAVA, Eisai, Exelixis, Ipsen, MSD, NiKang, and Novartis outside the submitted work. O. lliopoulos received consultancy fees from Merck. K.E. Beckermann reports support from MSD during the conduct of the study. K.E. Beckermann also reports grants from BMS-LCFA-IASLC, Arsenal Biosciences, Pionyr, Aravive, and the US Department of Defense, as well as consulting fees from Aravive, Aveo, Alpine Bioscience, BMS, Exelixis, Merck, Nimbus, Arcus, Xencor, Sanofi, AstraZeneca, and Seagen. V. Narayan reports grants from Merck during the conduct of the study. V. Narayan also reports consulting fees from AstraZeneca, Exelixis, Janssen, Merck & Co., Inc., Myovant Sciences, Pfizer Regeneron, and Sanofi, as well as research support (to institution) from Bristol Myers Squibb, Janssen, Merck & Co., Inc., Pfizer, Regeneron, and TMunity Therapeutics outside the submitted work. B.L. Maughan reports personal fees from AbbVie, Pfizer, Aveo Oncology, Janssen, Astellas, Tempus, MSD, Bayer Oncology, Lilly, Sanofi, Telix, and Peloton Therapeutics; grants and personal fees from Bristol Myers Squibb, Clovis, and Exelixis; and grants from Bavarian-Nordic and Genentech during the conduct of the study. B.L Maughan also reports working for Xencor as a consultant/advisor. S. Oudard reports honoraria from Astellas, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche/Genentech, and Sanofi; consulting to Astellas, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, and SD Oncology; research funding from Ipsen and Sanofi; and travel, accommodation, and expense reimbursements from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, MSD, Novartis, and Roche. J.K. Maranchie reports personal fees from Elsevier; grants from NCI; and other support from Janssen, LUGPA, and MSD during the conduct of the study. J.K. Maranchie also reports other support from SUO outside the submitted work. C.M. Goldberg is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and has stock ownership in Merck & Co. W. Fu is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. R.F. Perini is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., and has stock ownership in Merck & Co., Inc. Y. Liu is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. R. Srinivasan reports research funding (to institution) from MSD during the conduct of the study. No disclosures were reported by the other authors.

T. Else: Investigation, writing–review and editing. E. Jonasch: Conceptualization, writing–review and editing. O. lliopoulos: Conceptualization, resources, investigation, writing–review and editing. K.E. Beckermann: Resources, data curation, investigation, writing–review and editing. V. Narayan: Formal analysis, investigation, writing–review and editing. B.L. Maughan: Resources, data curation, investigation, writing–review and editing. S. Oudard: Formal analysis, investigation, writing–review and editing. J.K. Maranchie: Investigation, writing–review and editing. A.B. Iversen: Validation, investigation, writing–review and editing. C.M. Goldberg: Investigation, writing–review and editing. W. Fu: Conceptualization, formal analysis, investigation, writing–review and editing. R.F. Perini: Formal analysis, validation, investigation, writing–review and editing. Y. Liu: Investigation, writing–review and editing. W.M. Linehan: Conceptualization, investigation, writing–review and editing. R. Srinivasan: Conceptualization, resources, formal analysis, supervision, funding acquisition, validation, investigation, writing–review and editing.

We thank the patients and their families and caregivers for participating in the study. Medical writing and/or editorial assistance was provided by Mallory Campbell, PhD, and Robert Steger, PhD, of ApotheCom. This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and the Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI) Center for Cancer Research, and a grant (UO1 CA236489) from the NCI.